MannKind Corporation (MNKD) saw its stock surge 6.49% in after-hours trading on Wednesday, following the announcement of a strategic financing agreement with funds managed by Blackstone (BX). This significant uptick comes after a challenging regular trading session where the stock had fallen due to mixed Q2 2025 earnings results.

The financing deal, valued at up to $500 million, includes a $75 million initial term loan funded at closing, with additional options for future draws. The facility, set to mature in August 2030, bears interest at the secured overnight financing rate plus 4.75%. This substantial financial backing is expected to provide MannKind with increased flexibility to pursue its growth initiatives in inhaled therapeutics.

Earlier in the day, MannKind had reported its second-quarter earnings, which showed a 6% year-over-year increase in revenue to $76.5 million. However, this figure fell short of analyst expectations of $78.8 million. The company's non-GAAP earnings per share remained steady at $0.05, aligning with estimates. Despite the revenue miss, MannKind highlighted strong performance in its Afrezza inhaled insulin sales and royalty income from Tyvaso DPI.

The after-hours stock surge suggests that investors are optimistic about the long-term potential unlocked by the Blackstone financing agreement, overshadowing the slight disappointment from the Q2 earnings report. This deal could provide MannKind with the capital needed to advance its pipeline, including potential expansion of Afrezza into pediatric use and progress on its pulmonary hypertension treatments.